DOVA PHARMACUET’s Quiet Period Set To Expire on August 8th (NASDAQ:DOVA)

DOVA PHARMACUET’s (NASDAQ:DOVA) quiet period will end on Tuesday, August 8th. DOVA PHARMACUET had issued 4,415,000 shares in its initial public offering on June 29th. The total size of the offering was $75,055,000 based on an initial share price of $17.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

DOVA has been the topic of several analyst reports. Jefferies Group LLC assumed coverage on DOVA PHARMACUET in a research note on Monday, July 24th. They issued a “buy” rating and a $30.00 price target for the company. Leerink Swann assumed coverage on DOVA PHARMACUET in a research note on Monday, July 24th. They set a “market perform” rating and a $24.00 target price for the company. Finally, J P Morgan Chase & Co assumed coverage on DOVA PHARMACUET in a research note on Monday, July 24th. They set an “overweight” rating and a $35.00 target price for the company.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://transcriptdaily.com/2017/08/13/dova-pharmacuets-quiet-period-to-expire-on-august-8th-nasdaqdova-updated.html.

Shares of DOVA PHARMACUET (DOVA) opened at 18.25 on Friday. The stock’s market capitalization is $456.07 million. The stock’s 50 day moving average price is $20.97 and its 200-day moving average price is $20.97. DOVA PHARMACUET has a 1-year low of $12.03 and a 1-year high of $28.59.

DOVA PHARMACUET (NASDAQ:DOVA) last issued its earnings results on Thursday, August 10th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.08. Equities research analysts anticipate that DOVA PHARMACUET will post ($1.22) EPS for the current fiscal year.

In other DOVA PHARMACUET news, Director Steven M. Goldman bought 72,000 shares of DOVA PHARMACUET stock in a transaction on Wednesday, July 5th. The shares were purchased at an average price of $17.94 per share, with a total value of $1,291,680.00. Following the acquisition, the director now owns 42,000 shares in the company, valued at approximately $753,480. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Alex Sapir bought 20,100 shares of DOVA PHARMACUET stock in a transaction on Wednesday, July 5th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $341,700.00. Following the acquisition, the chief executive officer now owns 20,100 shares in the company, valued at approximately $341,700. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 101,800 shares of company stock worth $1,798,280.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Laurion Capital Management LP purchased a new position in shares of DOVA PHARMACUET during the second quarter worth approximately $223,000. JPMorgan Chase & Co. purchased a new position in shares of DOVA PHARMACUET during the second quarter worth approximately $382,000. Vanguard Group Inc. purchased a new position in shares of DOVA PHARMACUET during the second quarter worth approximately $390,000. Ameriprise Financial Inc. purchased a new position in shares of DOVA PHARMACUET during the second quarter worth approximately $668,000. Finally, Conning Inc. purchased a new position in shares of DOVA PHARMACUET during the second quarter worth approximately $1,115,000.

About DOVA PHARMACUET

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Receive News & Ratings for DOVA PHARMACUET Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DOVA PHARMACUET and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply